Status:
UNKNOWN
Developing a Diagnostic Tool to Predict Response to Chemotherapy
Lead Sponsor:
Nottingham University Hospitals NHS Trust
Collaborating Sponsors:
University of Nottingham
Nottingham Trent University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-90 years
Brief Summary
Every year nearly 62,000 people are diagnosed with breast cancer in the UK. One in eight women in the UK will develop breast cancer in their lifetime. The investigators are developing an inexpensive ...
Detailed Description
Approximately 16,700,000 people are diagnosed with breast cancer (BC) worldwide each year, with 500,000 people dying annually. In the UK alone, each year nearly 62,000 people are diagnosed with BC, wi...
Eligibility Criteria
Inclusion
- Histological diagnosis of primary invasive breast cancer.
- Any hormone receptor status (Oestrogen Receptor, Progesterone Receptor).
- Any Human epidermal growth factor receptor 2 (HER2) receptor status.
- 18 to 90 years old.
Exclusion
- Histological diagnosis of any other cancer type.
- Evidence of distant metastatic disease at diagnosis.
- Insufficient tumour tissue available for research use in tissue blocks held in the NUH Trust pathology archive.
- Outside of stated inclusion age range.
Key Trial Info
Start Date :
November 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2021
Estimated Enrollment :
4750 Patients enrolled
Trial Details
Trial ID
NCT04277195
Start Date
November 7 2019
End Date
May 31 2021
Last Update
February 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nottingham University Hospitals NHS Trust
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB